Comparison Between Ultra-narrow Diameter Implants (2,75 mm) Without Bone Regeneration Versus Standard Diameter Implants (4,3 mm) in Combination With Bone Regeneration

Éxito a Corto Plazo de Los Implantes Ultra-estrechos (2,75 mm) en comparación Con Implantes de Plataforma Regular (4,3 mm) Que Requieren regeneración ósea Vestibular simultánea. Ensayo clínico Aleatorizado

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03225495

Enrollment

Registered

2017-07-21

Start date

2017-07-01

Completion date

2019-07-01

Last updated

2018-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dental Implant, Guided Bone Regeneration, Implant Fracture, Narrow Implant

Brief summary

The main target of the study is to compare ultra-narrow diameter implants (2.75 mm) without bone regeneration versus standard diameter implants (4.3 mm) in combination with bone regeneration. To do so, patients with missing upper central incisors, canines, first or second premolars with alveolar ridges of 6 - 8 mm of thickness will be restored with dental implants. Cone beam computed tomographic examination and clinical values will be registered before and after the surgical procedure at 6 and 12 months.

Interventions

PROCEDUREStandard implant

Arm - Standard Implant: implant placement in combination with guided bone regeneration;

PROCEDUREUltra-narrow implant

Arm - Ultra-narrow implant: implant placement without guided bone regeneration

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* One missing teeth in position: upper central incisor, canine or premolar * alveolar ridge thickness of 6 - 8 mm * alveolar ridge height of ≥ 10 mm

Exclusion criteria

* Missing data * ASA ≥ III

Design outcomes

Primary

Measure	Time frame	Description
Success	12 months	According to criteria described by Albrektsson et al. 1986

Countries

Spain

Contacts

Primary ContactRui Figueiredo, PhD

ruipbfigueiredo@gmail.com00 34 93 402 42 74

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026